Although programmed cell death 1 (PD-1) inhibitors have been approved as the first-line treatment for advanced CRC with dMMR as a predictive biomarker for PD-1 ICIs, less than half of the patients with dMMR CRC respond favorably to anti-PD-1 therapy (3). Here, PDCD1 is linked to colorectal carcinoma.